Veradigm™, an Allscripts (NASDAQ:MDRX), business unit, announced today that it has strengthened its strategic relationship with Pulse8, a leader in healthcare analytics and technology company.
Pulse8 is the first, and only with a patent pending, healthcare analytics and technology company delivering a complete enterprise platform to provide visibility into the efficacy of Risk Adjustment, Quality Improvement, and Pharmacy Management programs. Pulse8 enables both health plans and at-risk providers to achieve precise risk and quality scores in the Medicare Advantage, Managed Medicaid, and ACA Commercial markets as well as with Value-Based Payment models for Medicare. Pulse8’s Illumin8™ Active Intelligence™ platform offers a suite of uniquely pragmatic solutions that are powered by patent-pending Dynamic Intervention Planning to deliver cost-effective and appropriate interventions for closing gaps in documentation, coding, and quality.
Pulse8 strengthens Veradigm’s existing health plan product suite that delivers tools and services to help control costs while optimizing health outcomes for health plan members. The newly combined offering of clinical data exchange solutions, cutting-edge analytics, and point-of-care engagement tools supports Veradigm’s commitment to health plans and health care providers in their drive towards quality outcomes while maximizing return on investment.
“The type of analytics, technology capabilities, and market knowledge that Pulse8 brings to our team complements and strengthens Veradigm’s existing health plan portfolio. John Criswell, CEO, Pulse8, will be responsible for leading our combined efforts,” said Tom Langan, CEO of Veradigm. “The move reflects our strategy to extend and enhance existing solutions in bold new ways to improve healthcare quality, risk score accuracy, and healthcare cost reduction.”
Read more here.